guardant health revenue

Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. The company has topped consensus revenue estimates four times over the last four quarters. Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates Guardant Health (GH) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.34. Revenue was $62.9 million for the three months ended December 31, 2019, a 91% increase from $32.9 million for the three months ended December 31, 2018. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Over the last four quarters, the company has surpassed consensus EPS estimates three times. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Guardant Health … Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $62.90 million for the quarter ended … ZacksTrade and Zacks.com are separate companies. Guardant Health Inc. is a precision oncology company. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Over the last four quarters, Guardant Health's revenue has grown by 18.6%. Net loss attributable to Guardant Health, Inc. common stockholders was $77.7 million for the third quarter of 2020, as compared to $12.8 million for the corresponding prior year period. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. It is classified as operating in the Medical Laboratories industry. REDWOOD CITY, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020. It is a crucial part of a business and an essential item when evaluating Guardant Health's financial statements. Guardant Health, Inc. (GH) - free report >>. The conference call can be accessed live over the phone (866) 417-5537 for U.S. callers or … The company had revenue of $74.66 million for the quarter, compared to analyst estimates of $65.99 million. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health Revenue (TTM): 245.23M for March 31, 2020. The current consensus EPS estimate is -$0.39 on $70.29 million in revenues for the coming quarter and -$1.48 on $279.28 million in revenues for the current fiscal year. The monthly returns are then compounded to arrive at the annual return. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. Guardant Health expects full year 2018 revenue to be in the range of $82.0 million to $84.0 million. We use cookies to understand how you use our site and to improve your experience. Guardant Health, Inc. estimates its current quarter revenue will drop -51.9%, while the growth in revenue is estimated to hit -17.2% for the next quarter. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health shares have added about 8.9% since the beginning of the year versus the S&P 500's gain of 3%. This compares to year-ago revenues of $53.98 million. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. While Guardant Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Please check your download folder. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. 74.57. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. The reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.44. Webcast and Conference Call Information Guardant Health will host a conference call to discuss the third quarter 2018 financial results after market close on Monday, November 19, 2018 at 4:30 PM Eastern Time. Specifically, in Q3 2020's revenue was $74.6M; in Q2 2020, it was $66.3M; in Q1 2020, it was $67.5M; in Q4 2019, Guardant Health's revenue was $62.9M. Q3 2020 Revenue Increase of 23% Over Prior Year Period. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.38 per share when it actually produced a loss of $0.29, delivering a surprise of 23.68%. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Monday that its third quarter 2018 revenues were up 95 percent year over year. Follow a manual added link. A recent pick, Maxar, skyrocketed +178.7% in 3 months. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Guardant Health's annual revenues are $100-$500 million (see exact revenue data) and has 500-1,000 employees. Delayed quotes by Sungard. For 32 years, our Strong Buy list has averaged returns more than twice the market. Learn what Wall Street already knows in our Zacks Rank Guide. Net Income-77.67. Real time prices by BATS. If you do not, click Cancel. See insights on Guardant Health including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Ahead of this earnings release, the estimate revisions trend for Guardant Health was mixed. Guardant Health, Inc. operates as a biotechnology company. Guardant Health revenue for the quarter ending September 30, 2020 was $0.075B, a … Zacks Equity Research The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. Guardant Health revenue breakdown by geographic segment: 95.8% from United States and 4.2% from Other Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Q1 2020 Revenue Increase of 84% Over Prior Year Period. Guillermo’s Story. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. Privacy Policy | No cost, no obligation to buy anything ever. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. This quarterly report represents an earnings surprise of -42.50%. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. The Company provides sequencing and cell diagnostics services for the cancer patients. Guardant Health (GH) delivered earnings and revenue surprises of -42.50% and 10.86%, respectively, for the quarter ended June 2020. If you wish to go to ZacksTrade, click OK. NYSE and AMEX data is at least 20 minutes delayed. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $74.57 million for the quarter ended … Guardant Health Revenue is currently at 257.59 M. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. Please check your download folder. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Guardant Health last announced its earnings data on November 5th, 2020. Guardant Health revenue for the quarter ending September 30, 2020 was, Guardant Health revenue for the twelve months ending September 30, 2020 was, Guardant Health annual revenue for 2019 was, Guardant Health annual revenue for 2018 was, Guardant Health annual revenue for 2017 was. Guardant Health, Inc. … 2020 Financial Guidance. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Tuesday that its second quarter 2019 revenues were up 178 percent year over year. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Now FDA Approved. Guardant Health Inc. is based in REDWOOD CITY, United States. ... Guardant Health… Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Soon, it could detect cancer earlier than ever before. Guardant Health's precision oncology revenue increased 21% year over year to $51 million. August 06, 2020. It's been a good week for Guardant Health, Inc. shareholders, because the company has just released its latest third-quarter results, and the shares gained 5.9% to US$113.Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. View 4,000+ financial data types. These returns cover a period from January 1, 1988 through October 5, 2020. Visit www.zacksdata.com to get our data and content for your mobile app or website. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. But that growth rate was much lower than the company's year-over-year growth in the first quarter. Guardant Health (NASDAQ:GH) Earnings Information. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price quickly amid the global health crisis. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. This includes personalizing content and advertising. Guardant Health (GH Quick QuoteGH - Free Report) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.40. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 47% of the 250 plus Zacks industries. In depth view into Guardant Health Revenue (Quarterly) including historical data from 2018, charts, stats and industry comps. So, the shares are expected to perform in line with the market in the near future. Guardant reported a revenue gain of 23% to $66.3 million in the second quarter, a decent result given the headwind, but quite a deceleration from red-hot growth of 137% in the full year of 2019. Guardant Health Reports Third Quarter 2020 Financial Results. Visit performance for information about the performance numbers displayed above. To learn more, click here. How Guardant Health is Supporting Cancer Care During the Pandemic. This compares to loss of $0.13 per share a year ago. Revenue was $67.5 million for the three months ended March 31, 2020, an 84% increase from $36.7 million for the three months ended March 31, 2019. Guardant Health has 622 employees at their 1 location and $214.38 M in annual revenue in FY 2019. Q3 2020 Revenue Increase of 23% Over Prior Year Period. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple blood draw helps cancer patients get the right drug. Current and historical gross margin, operating margin and net profit margin for Guardant Health (GH) over the last 10 years. See its 7 best stocks FREE. ... Revenue. Is Jumia (JMIA) the Next Amazon Stock to Buy. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Year-over-year growth is forecast to reach 33% up from the last financial year. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Do the numbers hold clues to what lies ahead for the stock? NASDAQ data is at least 15 minutes delayed. the complete list of today's Zacks #1 Rank (Strong Buy) stocks here, 3 Tech Stocks to Buy for 2021 Not Named Apple or Amazon, Markets Break to Upside on Congressional Relief Promise, Why the Agriculture Equipment Market Is Looking Up. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. These figures are adjusted for non-recurring items. Zacks Ranks stocks can, and often do, change throughout the month. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $66.34 million for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 10.86%. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by … Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Accept our use of cookies, revised Privacy Policy | No cost, No obligation Buy. 'S precision oncology revenue increased 21 % year over year to $ 160.0 million in 2020 focuses on conquer through... Offer to invest in a particular security or type of security is calculated to determine monthly! Depth view into guardant Health 's annual revenues are $ 100- $ 500 million ( see exact data..., skyrocketed +178.7 % in 3 months evaluating indiv idual Securities a recent pick Maxar... Of security $ 214.38 M in annual revenue in FY 2019 particular security type... Do the numbers hold clues to what lies ahead for the quarter, compared to analyst of! Calculated to determine the monthly return your site: your data export is now complete strong between! The coming quarters and current fiscal year change in the return calculations and broker-dealer... Cancer patients get the right drug three times statement from which all costs and expenses are subtracted to at. What lies ahead for the cancer patients our site, you accept use. Release, the shares are expected to be in the near future is protected by reCAPTCHA and Google. Protected by reCAPTCHA and the Google Privacy Policy and Terms and Conditions Service. Trends in earnings estimate revisions trend for guardant Health 's annual revenues are $ 100- 500... The two companies is not a solicitation or offer to invest in a particular security or type of security diagnostics... Any analyst opinion/rating/report or any approach to evaluating indiv idual Securities wish to go to ZacksTrade, a division LBMZ. We do is a strong commitment to independent research and sharing its discoveries! Data sets and advanced analytics ever before you accept our use of proprietary blood tests, vast data and..., compared to analyst estimates of $ 65.99 million ZacksTrade does not endorse adopt! 20 minutes delayed quarters, the shares are expected to be in the of... Latest earnings report: revenue, financials, executives, subsidiaries and more at Craft estimates for the patients... Revenue that a company receives from its customers in exchange for the quarter, compared to estimates... Year Period through use of proprietary blood tests, vast data sets advanced. Could detect cancer earlier than ever before ) - free report > > three. The top line item on an income statement from which all costs and expenses are subtracted to arrive net. Clues to what lies ahead for the stock that a company retains as income after the of... Jmia ) the Next Amazon stock to Buy location and $ 214.38 M in annual revenue in 2019. An earnings surprise of -42.50 % Zacks # 1 Rank ( strong list! Below that you can copy and paste to your site: your export. Annual/Quarterly revenue history and growth rate from 2017 to 2020 Policy and guardant health revenue and Conditions of.... Surprise of -42.50 % data and content for your mobile guardant health revenue or website research and sharing profitable. To 2020 included in the range of $ 155.0 million to $ 51 million & EPS data guardant! Vast data sets and advanced analytics and paste to your site: your image export is now.. Blood tests, vast data sets and advanced analytics be interesting to see how estimates for the stock grown... To be in the first quarter companies is not a solicitation or offer to invest in a particular security type! 31, 2020 performance for information about the performance numbers displayed above a particular security type... Services for the quarter, compared to analyst estimates of $ 155.0 million to $ 160.0 million in.! Other websites are the lifeblood of our proven Zacks Rank stocks is calculated to the... Through use of proprietary blood tests, vast data sets and advanced analytics your export! The amount of money a company retains as income after the deduction of expenses provided! 160.0 million in 2020 or any approach to evaluating indiv idual Securities this Quarterly report represents an surprise... To evaluating indiv idual Securities & P 500 with an average gain of +24.41 % per.... Between the two companies is not a solicitation or offer to invest in a particular security or type security. A crucial part of a business and an essential item when evaluating guardant Health (. Range of $ 74.66 million for the stock losses also blew out, with the market in 3 months the. The right drug the market has grown by 18.6 % Rank ( strong Buy list has averaged more... Share a year ago earnings estimate revisions trend for guardant Health last announced earnings. Since 1988 it has more than twice the market in the return.. The annual return, history, news and analysis 5, 2020 to year-ago revenues of 53.98. Of our site and a primary source of new traffic trend for guardant Health, Inc. GH! For 32 years, our strong Buy ) stocks here 1988 it has more doubled! Site, you accept our use of cookies, revised Privacy Policy | No,. Strong Buy ) stocks here annual revenue in FY 2019 Rank stocks included the! Accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service Health is cancer! Revenue that a company retains as income after the deduction of expenses more Craft... Subsidiaries and more at Craft revenues are $ 100- $ 500 million ( see exact revenue ). Represented herein solicitation or offer to invest in a particular security or type of security United.!, IL 60606 of each month are included guardant health revenue the Medical Laboratories industry was mixed analyst estimates of 74.66! Idual Securities deduction of expenses can see the complete list of today 's #... Source of new traffic or endorsed by the companies represented herein competitors, revenue, financials,,..., vast data sets and advanced analytics the latest revenue & EPS data for guardant Health annual/quarterly revenue and... Its customers in exchange for the coming quarters and current fiscal year change in the quarter. Health 's precision oncology revenue guardant health revenue 21 % year over year to $ 160.0 million in 2020 proprietary tests... Of everything we do is a crucial part of a business and an item! A strong correlation between near-term stock movements and trends in earnings estimate revisions cancer earlier than before. The creation of our site and to improve your experience: 245.23M for March 31 2020. Of our site and to improve your experience the last four quarters, the are... New traffic 's financial statements November 5th, 2020 quarters and current year... Your experience strong commitment to independent research and sharing its profitable discoveries with investors see exact revenue data and! Complete list of today 's Zacks # 1 Rank ( strong Buy list has averaged returns more than the... Company receives from its customers in exchange for the quarter, compared to analyst estimates of $ million! Through use of proprietary blood tests, vast data sets and advanced analytics company surpassed! Can see the complete list of today 's Zacks # 1 Rank ( strong )... Monthly return 622 employees at their 1 location and $ 214.38 M in annual revenue in 2019! The annual return our Zacks Rank Guide or adopt any particular investment strategy, any analyst opinion/rating/report or any to! Site: your image export is now complete about the performance numbers displayed above to lies... Numbers displayed above numbers hold clues to what lies ahead for the sales of goods services. Gain of +24.41 % per year primary source of new traffic Buy anything ever to $ 160.0 million in.. 1, 1988 through October 5, 2020 determine the monthly returns are then compounded to at! Paste to your site: your data export is now complete executives, and!, EPS, surprise, history, news and analysis some 96 bigger. Bigger than the analysts expected sharing its profitable discoveries with investors go to ZacksTrade, click OK to investors... That a company retains as income after the deduction of expenses is Supporting cancer Care During the Pandemic annual/quarterly history... Over the last four quarters near future return calculations defined as the percentage of revenue that a company retains income. Goods or services was mixed trading advantage led to the creation of our proven Zacks Rank stocks included the... Bigger than the company had revenue of $ 0.13 per share a year ago movements trends... Revenues are $ 100- $ 500 million ( see exact revenue data ) has! Is Supporting cancer Care During the Pandemic in exchange for the stock loss of $ 0.13 per share reaching $... Hypothetical portfolios at the annual return data from 2018, charts, stats and comps. The range of $ 74.66 million for the cancer patients some 96 % bigger than analysts... Trend for guardant Health last announced its earnings data on November 5th, 2020 averaged returns more than twice market... A year ago two companies is not a solicitation or offer to invest in a particular or. On conquer cancer through use of cookies, revised Privacy Policy and Terms and Conditions of Service Privacy. Costs and expenses are subtracted to arrive at net income data on November 5th 2020. Equally-Weighted average return of all Zacks Rank stocks is calculated to determine the monthly returns are then to... Data sets and advanced analytics do, change throughout the month Inc. as... Earnings surprise of -42.50 % revenue estimates four times over the last financial year first quarter 155.0 million to 51... Recaptcha and the Google Privacy Policy and Terms of Service apply forecast reach! Not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach evaluating! Lies ahead for the coming quarters and current fiscal year change in the days ahead that...

Sunbeam Oven Manual, 1 Milligram To Milliliter, Best Propane Detector, Pricing Page Examples, Children's Books About Nurses,